Full Papers
Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry
J.-Y. Jung1, E. Lee2, J.-W. Kim3, C.-H. Suh4, H.-A. Kim5
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
- Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Korea.
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea. nakhada@naver.com
CER15698
2023 Vol.41, N°5
PI 1034, PF 1041
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 36062753 [PubMed]
Received: 21/03/2022
Accepted : 21/07/2022
In Press: 31/08/2022
Published: 03/05/2023
Abstract
OBJECTIVES:
Janus kinase inhibitors are expected to change the management patterns and prognosis of chronic rheumatic diseases. This study aimed to evaluate the efficacy, drug retention, and adverse events of tofacitinib, a Janus kinase inhibitor, for rheumatoid arthritis (RA) using a Korean nationwide database.
METHODS:
Data of patients with RA receiving tofacitinib were extracted from the Korean College of Rheumatology Biologics and Targeted Therapy registry, including clinical characteristics and disease activity markers for RA. Outcomes of clinical efficacy, drug survival rate, and safety profiles were compared between biologic disease-modifying anti-rheumatic drug (bDMARD)-naive and -failure patients. Mann-Whitney U-test, logistic regression analysis, Kaplan-Meier analysis, and log-rank test were used in data analysis.
RESULTS:
Three hundred patients with RA received tofacitinib therapy (16.3% male; mean age 55.4±11.9 years); 91 patients were bDMARD-naive. Baseline disease activity markers and proportions of patients who were taking conventional synthetic DMARDs were not different between bDMARD-naive and bDMARD-failure patients. American College of Rheumatology responses and disease activity score-28 did not differ between bDMARD-failure and -naive patients at the 1-year follow-up. The drug retention rate of tofacitinib did not differ between bDMARD-failure (155 per 2.4 years) and -naive patients (89 per 1.9 years) (log-rank test, p=0.202). In logistic regression, the positivity of RF and ACPA were associated with reduced drug retention (p=0.01 and 0.02, respectively). Totally 83 (27.7%) of patients had adverse, and 14 (4.7%) patients had herpes zoster infection.
CONCLUSIONS:
Nationwide real-world data showed that tofacitinib therapy is effective in patients with RA independent of previous use of a bDMARD. The drug retention of tofacitinib did not differ between bDMARD-failure and -naive patients, and RF or ACPA positivity may be associated with reduced discontinuation of tofacitinib.
